Healthcare Industry News: Surgical Hemostat
News Release - May 15, 2008
Haemacure appoints Reinaldo M. Diaz to its Board of Directors
MONTREAL, May 15 (HSMN NewsFeed) - Haemacure Corporation (TSX:HAE ), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announced today the appointment of Reinaldo M. Diaz as a new member of the Board of Directors' of the Company.About Reinaldo M. Diaz
Mr. Diaz has over 25 years of experience in the biopharmaceutical industry. He currently serves as a Managing Director of Celtic Pharma Management, L.P. a global equity firm focused on the pharmaceutical industry. Prior to joining Celtic Pharma, Mr. Diaz was Managing Member and Co-Founder of D&A Capital Management, LLC ("D&A Capital"), a firm focused on asset management and providing advisory services to companies in the healthcare sector, particularly biopharmaceutical companies. From 1993 to 1996, Reinaldo was Managing Director and Head of the Healthcare group at Schroder Wertheim & Co., Inc. In that capacity, he was responsible for establishing and expanding Schroder Wertheim's investment banking presence in the healthcare industry. From 1981 to 1993, Reinaldo was with PaineWebber, Inc. During his tenure at PaineWebber, he was a key member of the PaineWebber Healthcare Investment Banking Group and of PaineWebber Development Corporation. He became President of PaineWebber Development Corporation in 1990, having been a managing director prior to that time.
"I am pleased to join Haemacure's Board of Directors and look forward to working with Joseph Galli, Haemacure's management team and other board members to help Haemacure achieve its product development and commercial goals," said Mr. Diaz.
About Haemacure
Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including Surgical Hemostats. Haemacure's lead product candidate, Hemaseel®HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on Surgical Hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.
Source: Haemacure
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
